AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20716817 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine (low and mid-dose)
Number of subjects: 30
Study 20716817 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 vaccine
Number of subjects: 30
Study 20716817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17929487 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of a local anesthetic
Number of subjects: 48
Study 17929487 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 48
Study 15546807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge containing lavender oil, extracts from hops, lemon balm and oat
Number of subjects: 16
Study 15546807 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge without active ingredients
Number of subjects: 16
Study 11177061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (5 hours of experiential instruction on injury prevention content and counseling skills)
Number of subjects: 196
Study 11177061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 196
Study 11177061 — intervention group
Group type: COMPARATOR
Intervention: Control group (1-hour seminar about injury prevention and TIPP materials)
Number of subjects: 196
Study 11177061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group and Control group
Number of subjects: 196
Study 9661080 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg/day; n = 12)
Number of subjects: 24
Study 9661080 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study 7817022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, immediate vitrectomy
Number of subjects: 34
Study 7817022 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal amikacin and vancomycin, subconjunctival and topical antimicrobials and corticosteroids, systemic corticosteroids, vitreous tap and treatment with or without intravenous antibiotics
Number of subjects: 34
Study 3178249 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical bufexamac
Number of subjects: 10
Study 3178249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31216961 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus with distal location
Number of subjects: 408
Study 31216961 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher clot burden score (CBS)
Number of subjects: 408
Study 31216961 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter thrombus length
Number of subjects: 408
Study 31216961 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus perviousness
Number of subjects: 408
Study 31216961 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal thrombi
Number of subjects: 408
Study 28622349 — intervention group
Group type: EXPERIMENTAL
Intervention: Running 5 km at maximal speed
Number of subjects: 17
Study 28622349 — intervention group
Group type: COMPARATOR
Intervention: Day of rest (control)
Number of subjects: 17
Study 26039968 — intervention group
Group type: EXPERIMENTAL
Intervention: AfH (AutoSet for her)
Number of subjects: 20
Study 26039968 — intervention group
Group type: COMPARATOR
Intervention: AutoSet
Number of subjects: 20
Study 23211042 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis (CP) in ED group
Number of subjects: 162
Study 23211042 — intervention group
Group type: COMPARATOR
Intervention: Chronic periodontitis (CP) in non-ED group
Number of subjects: 162
Study 23211042 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque index (PI), bleeding on probing (BoP), probing depth (PD), clinical attachment level (CAL) in ED group
Number of subjects: 162
Study 23211042 — intervention group
Group type: EXPERIMENTAL
Intervention: Decayed, missing, filled teeth scores in ED group
Number of subjects: 162
Study 23211042 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of ED and CP severity
Number of subjects: 162
Study 22120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 74
Study 22120857 — intervention group
Group type: COMPARATOR
Intervention: Enalapril or Amlodipine without Atorvastatin
Number of subjects: 74
Study 22120857 — intervention group
Group type: COMPARATOR
Intervention: Healthy Volunteers
Number of subjects: 74
Study 22120857 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive Patients
Number of subjects: 74
Study 19168326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 150
Study 19168326 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 150
Study 19168326 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratiopeptidase
Number of subjects: 150
Study 19168326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15254494 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous serum application (20% diluted with physiological saline, applied four times a day for up to 12 weeks)
Number of subjects: 42
Study 15254494 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic and autologous serum
Number of subjects: 42
Study 15254494 — intervention group
Group type: COMPARATOR
Intervention: Control group (antibiotic alone)
Number of subjects: 42
Study 15254494 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical autologous serum application
Number of subjects: 42
Study 12198602 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 519
Study 12198602 — intervention group
Group type: EXPERIMENTAL
Intervention: Coeliac disease
Number of subjects: 519
Study 12198602 — intervention group
Group type: EXPERIMENTAL
Intervention: LADA
Number of subjects: 519
Study 12198602 — intervention group
Group type: COMPARATOR
Intervention: MS
Number of subjects: 519
Study 12198602 — intervention group
Group type: COMPARATOR
Intervention: ATD
Number of subjects: 519
Study 12198602 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 519
Study 9787367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily
Number of subjects: 242
Study 9787367 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide (2%) three times daily and timolol (0.5%) twice daily
Number of subjects: 242
Study 9787367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2% dorzolamide and 0.5% timolol) given twice daily during open-label extension
Number of subjects: 242
Study 7616872 — intervention group
Group type: COMPARATOR
Intervention: Estradiol implants 50 mg alone (E)
Number of subjects: 34
Study 7616872 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 50 mg plus testosterone 50 mg (E&T)
Number of subjects: 34
Study 2239120 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital 80 mg/ml, 20 mg/kg rectally, 15 min before transportation
Number of subjects: 30
Study 2239120 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital 28 mg/ml, 7 mg/kg rectally, 45 min before transportation
Number of subjects: 30
Study 366263 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 1% and 3% eye drops
Number of subjects: 0
Study 31827357 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive walking program (continuous for weeks 1-8 and interval for weeks 9-17)
Number of subjects: 15
Study 31827357 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and stair-climbing group (includes stair climbing)
Number of subjects: 15
Study 31827357 — intervention group
Group type: COMPARATOR
Intervention: Progressive walking program
Number of subjects: 15
Study 31827357 — intervention group
Group type: COMPARATOR
Intervention: Walking and stair-climbing group
Number of subjects: 15
Study 28681535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMBs) present in 30% of patients
Number of subjects: 1278
Study 28681535 — intervention group
Group type: EXPERIMENTAL
Intervention: CMBs
Number of subjects: 1278
Study 28681535 — intervention group
Group type: COMPARATOR
Intervention: Treatment assignments (aspirin/clopidogrel vs aspirin/placebo)
Number of subjects: 1278
Study 26220871 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based support (weekly for 12 weeks, 15-25 min/week)
Number of subjects: 120
Study 26220871 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (control group)
Number of subjects: 120
Study 26220871 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation (cost-effectiveness and cost-utility analysis)
Number of subjects: 120
Study 26220871 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 120
Study 23958393 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg per day)
Number of subjects: 60
Study 23958393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl (60 mg per day)
Number of subjects: 60
Study 23958393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 60
Study 21030499 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (≥4 cups/day)
Number of subjects: 359
Study 21030499 — intervention group
Group type: COMPARATOR
Intervention: Nondrinkers of caffeinated coffee
Number of subjects: 359
Study 21030499 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (≥4 cups/day) after adjusting for SHBG
Number of subjects: 359
Study 18985740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant triple therapy (125 mg p.o. on day 1, 80 mg on days 2 and 3, and 4 mg dexamethasone and ondansetron as specified)
Number of subjects: 46
Study 18985740 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (16 mg dexamethasone and ondansetron as specified)
Number of subjects: 46
Study 18985740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant triple therapy
Number of subjects: 46
Study 18985740 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 46
Study 17097819 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drinks (M=0.114 g% breath alcohol concentration [BrAC])
Number of subjects: 189
Study 17097819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 15053888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP)
Number of subjects: 339
Study 15053888 — intervention group
Group type: COMPARATOR
Intervention: Junior Medical Staff (JMS)
Number of subjects: 339
Study 11589530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 to 200 mg/day
Number of subjects: 132
Study 9465440 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical intention
Number of subjects: 73
Study 9465440 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated exposure
Number of subjects: 73
Study 9465440 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive deep muscle relaxation training
Number of subjects: 73
Study 7695265 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and rifampin
Number of subjects: 20
Study 7695265 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline and streptomycin
Number of subjects: 20
Study 2907877 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ofloxacin orally
Number of subjects: 11
Study 2907877 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin orally
Number of subjects: 11
Study 2907877 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ofloxacin intravenously
Number of subjects: 11
Study 2907877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29515226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 0
Study 29515226 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine (control)
Number of subjects: 0
Study 27992017 — intervention group
Group type: EXPERIMENTAL
Intervention: Video resources (bedside orientation with a short video and slide presentation)
Number of subjects: 90
Study 27992017 — intervention group
Group type: COMPARATOR
Intervention: Standard orientation (control group)
Number of subjects: 90
Study 27992017 — intervention group
Group type: EXPERIMENTAL
Intervention: Video resources (surgical room topic)
Number of subjects: 90
Study 27992017 — intervention group
Group type: EXPERIMENTAL
Intervention: Video resources (postoperative unit topic)
Number of subjects: 90
Study 27992017 — intervention group
Group type: EXPERIMENTAL
Intervention: Video resources (ventilatory support topic)
Number of subjects: 90
Study 25336467 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 406
Study 23822534 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading for understanding
Number of subjects: 183
Study 23822534 — intervention group
Group type: COMPARATOR
Intervention: Reading to solve a problem
Number of subjects: 183
Study 23822534 — intervention group
Group type: EXPERIMENTAL
Intervention: Think-aloud methodology
Number of subjects: 183
Study 20827028 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 16
Study 18157705 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (800 mg once-daily for 8 days)
Number of subjects: 16
Study 18157705 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal liver function)
Number of subjects: 16
Study 15705041 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stretching (n = 5)
Number of subjects: 19
Study 15705041 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (n = 5)
Number of subjects: 19
Study 15705041 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF-R) (n = 5)
Number of subjects: 19
Study 15705041 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 4)
Number of subjects: 19
Study 11876224 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow, high pressure
Number of subjects: 40
Study 11876224 — intervention group
Group type: COMPARATOR
Intervention: Low flow, low pressure
Number of subjects: 40
Study 10081544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 60
Study 10081544 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 60
Study 10081544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sevoflurane and isoflurane anesthesia
Number of subjects: 60
Study 7752178 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 or 100 mg/day)
Number of subjects: 438
Study 7752178 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 or 40 mg/day)
Number of subjects: 438
Study 7752178 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 438
Study 2261364 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 1127
Study 2261364 — intervention group
Group type: EXPERIMENTAL
Intervention: Single course of cytotoxic therapy
Number of subjects: 1127
Study 2261364 — intervention group
Group type: EXPERIMENTAL
Intervention: Single course of cytotoxic chemotherapy
Number of subjects: 1127
Study 2261364 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged adjuvant therapy (6 or 7 courses)
Number of subjects: 1127
Study 2261364 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged cytotoxic therapy
Number of subjects: 1127
Study 2261364 — intervention group
Group type: COMPARATOR
Intervention: Prolonged therapy vs. one single course among node-positive patients
Number of subjects: 1127
Study 399099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 20
Study 399099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31338642 — intervention group
Group type: EXPERIMENTAL
Intervention: sHNA (online prostate cancer-specific holistic needs assessment)
Number of subjects: 41
Study 31338642 — intervention group
Group type: EXPERIMENTAL
Intervention: sHNA
Number of subjects: 41
Study 31753895 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum, B. infantis, Lactobacillus acidophilus)
Number of subjects: 654
Study 31753895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 28838685 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 25 μg BID
Number of subjects: 1294
Study 28838685 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 50 μg BID
Number of subjects: 1294
Study 28838685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1294
Study 26365448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmical Massage (RM)
Number of subjects: 118
Study 26365448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma Oil (RA)
Number of subjects: 118
Study 26365448 — intervention group
Group type: COMPARATOR
Intervention: Sham Massage (SM)
Number of subjects: 118
Study 26365448 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary Cortisol
Number of subjects: 118
Study 23278283 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 809
Study 23278283 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 809
Study 23278283 — intervention group
Group type: COMPARATOR
Intervention: Clinical and demographic variables
Number of subjects: 809
Study 21282425 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral dose of efavirenz
Number of subjects: 10
Study 21282425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21282425 — intervention group
Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 10
Study 19034460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 50
Study 19034460 — intervention group
Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 50
Study 16459222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet with 30 g of soy protein and 4 g of phytosterols per day (LGID)
Number of subjects: 59
Study 16459222 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary program (American Heart Association Step 1 diet; AHAD)
Number of subjects: 59
Study 14972080 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 18
Study 14972080 — intervention group
Group type: COMPARATOR
Intervention: Conventional neuroleptics
Number of subjects: 18
Study 11731893 — intervention group
Group type: COMPARATOR
Intervention: Phototherapy
Number of subjects: 31
Study 10919427 — intervention group
Group type: EXPERIMENTAL
Intervention: High moisture‐conserving performance (Group H)
Number of subjects: 58
Study 10919427 — intervention group
Group type: COMPARATOR
Intervention: Low moisture‐conserving performance (Group L)
Number of subjects: 58
Study 10919427 — intervention group
Group type: EXPERIMENTAL
Intervention: High humidity
Number of subjects: 58
Study 10919427 — intervention group
Group type: COMPARATOR
Intervention: Low humidity
Number of subjects: 58
Study 8995494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (Navelbine) at 80 mg/m2 per week after ingestion of a standard meal
Number of subjects: 13
Study 8995494 — intervention group
Group type: COMPARATOR
Intervention: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in fasting state
Number of subjects: 13
Study 8995494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (Navelbine) at 80 mg/m2 per week in two divided doses
Number of subjects: 13
Study 8995494 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral administration of vinorelbine in two divided doses
Number of subjects: 13
Study 1431363 — intervention group
Group type: EXPERIMENTAL
Intervention: CFPM 2 g/day
Number of subjects: 72
Study 1431363 — intervention group
Group type: EXPERIMENTAL
Intervention: CFPM 4 g/day
Number of subjects: 72
Study 1431363 — intervention group
Group type: COMPARATOR
Intervention: CAZ 2 g/day
Number of subjects: 72
Study 4051271 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intratracheal aerosolized etidocaine
Number of subjects: 45
Study 4051271 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg intratracheal aerosolized etidocaine
Number of subjects: 45
Study 4051271 — intervention group
Group type: COMPARATOR
Intervention: No intratracheal aerosol (Control)
Number of subjects: 45
Study 30189822 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 275
Study 30189822 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anaesthesia
Number of subjects: 275
Study 26362539 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback‐based app (Nike + Running)
Number of subjects: 28
Study 26362539 — intervention group
Group type: COMPARATOR
Intervention: Game-based app (Zombies Run!)
Number of subjects: 28
Study 24362359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hassle Free Mealtimes Triple P (HFMTP); 2-hour discussion group on positive parenting strategies
Number of subjects: 86
Study 24362359 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 86
Study 21928099 — intervention group
Group type: EXPERIMENTAL
Intervention: GF Strong Water Protocol (GFSWP) - oral water intake, independent or supervised access, safe swallowing strategies
Number of subjects: 15
Study 21928099 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control phase) - no water access
Number of subjects: 15
Study 20039425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 4 mg/kg or 8 mg/kg plus methotrexate (MTX)
Number of subjects: 416
Study 20039425 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 416
Study 20039425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) plus methotrexate (MTX)
Number of subjects: 416
Study 17667889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IV thrombolytic therapy)
Number of subjects: 0
Study 17667889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IA thrombolysis)
Number of subjects: 0
Study 17667889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IV and IA thrombolysis
Number of subjects: 0
Study 17667889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 0
Study 17667889 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty and stenting procedures
Number of subjects: 0
Study 16257877 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization method
Number of subjects: 459